John Kishel, MD
Urology · Columbia, MDNPI 1144394107
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,091 of the $2,486 with a category attached, or 84.1%. It is spread thinly across 25 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,363 and has fallen 98.1% since, to $26 in 2025. That places this record below the midpoint for urology clinicians in MD, where the typical reported total is $4,190.
Across 123 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$340
- Johnson & Johnson$283
- Antares Pharma, Inc.$260
- Endo Pharmaceuticals Inc.$220
- AbbVie$173
- Coloplast$147
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,09184%
- Education$39516%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 17 | $340 |
| Johnson & Johnson(2 entities) | 16 | $283 |
| Antares Pharma, Inc. | 16 | $260 |
| Endo Pharmaceuticals Inc. | 12 | $220 |
| AbbVie(2 entities) | 10 | $173 |
| Coloplast | 7 | $147 |
| Seagen Inc. | 2 | $122 |
| Dendreon Pharmaceuticals LLC | 5 | $113 |
| Pfizer | 7 | $105 |
| Urogen Pharma, Inc. | 2 | $96 |
| Amgen | 5 | $95 |
| Janssen Scientific Affairs, LLC | 2 | $68 |
| Bayer | 2 | $68 |
| Ferring Pharmaceuticals Inc. | 4 | $67 |
| Tolmar Pharmaceuticals, Inc. | 3 | $59 |
| 180 Medical, Inc. | 2 | $50 |
| Myriad Genetic Laboratories, Inc. | 3 | $44 |
| Rochester Medical Corporation | 1 | $33 |
| Novartis | 1 | $26 |
| Urovant Sciences Inc | 1 | $23 |
| Mission Pharmacal Company | 1 | $21 |
| Neotract Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $17 |
How this compares
$2,486 in reported general payments places this provider in the 40th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 98 | $1,852 |
| Finasteride | 84 | $1,708 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $471 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 27 | $62 |
Paid to pharmacies, not to this prescriber.
Other urology in Columbia
- David FenigColumbia$26K
- Frank NezuColumbia$15K
- Nathaly FrancoisColumbia$12K
- Matthew AllawayCumberland$20.6M
- Benjamin LowentrittBaltimore$549K
- Julio DavalosGlen Burnie$490K
- Sankar KausikBel Air$375K
- Laura GiustoOwings Mills$367K
- Amin HeratiBaltimore$160K
- Rian DicksteinHanover$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.